Tafasitamab-cxix
Brand names: Monjuvi · Active ingredient: Tafasitamab
In short: MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
What is Tafasitamab-cxix used for?
MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
This indication is approved under accelerated approval based on overall response rate
. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Tafasitamab-cxix dosage
The recommended dose of MONJUVI is 12 mg/kg based on actual body weight administered as an intravenous infusion according to the dosing schedule in Table 1.
Administer MONJUVI in combination with lenalidomide 25 mg for a maximum of 12 cycles, then continue MONJUVI as monotherapy until disease progression or unacceptable toxicity
. Refer to the lenalidomide prescribing information for lenalidomide dosage recommendations.
Cycle
Each treatment cycle is 28-days. | Dosing Schedule
Cycle 1 | Days 1, 4, 8, 15 and 22
Cycles 2 and 3 | Days 1, 8, 15 and 22
Cycle 4 and beyond | Days 1 and 15
MONJUVI should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions (IRRs)
.
Administer premedications 30 minutes to 2 hours prior to starting MONJUVI infusion to minimize infusion-related reactions
.
Premedications may include acetaminophen, histamine H
1receptor antagonists, histamine H
2receptor antagonists, and/or glucocorticosteroids.
For patients not experiencing infusion-related reactions during the first 3 infusions, premedication is optional for subsequent infusions.
If a patient experiences an infusion-related reaction, administer premedications before each subsequent infusion.
The recommended dosage modifications for adverse reactions are summarized in Table 2.
Adverse Reaction | Severity | Dosage Modification
Infusion-related reactions
| Grade 2 (moderate) | Interrupt infusion immediately and manage signs and symptoms.
Once signs and symptoms resolve or reduce to Grade 1, resume infusion at no more than 50% of the rate at which the reaction occurred. If the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to the rate at which the reaction occurred.
Grade 3 (severe) | Interrupt infusion immediately and manage signs and symptoms.
Once signs and symptoms resolve or reduce to Grade 1, resume infusion at no more than 25% of the rate at which the reaction occurred. If the patient does not experience further reaction within 1 hour and vital signs are stable, the infusion rate may be increased every 30 minutes as tolerated to a maximum of 50% of the rate at which the reaction occurred.
If after rechallenge the reaction returns, stop the infusion immediately.
Grade 4 (life-threatening) | Stop the infusion immediately and permanently discontinue MONJUVI.
Myelosuppression
| Platelet count of 50,000/ mcL or less | Withhold MONJUVI and lenalidomide and monitor complete blood count (CBC) weekly until platelet count is 50,000/mcL or higher.
Resume MONJUVI at the same dose and lenalidomide at a reduced dose. …
How to take Tafasitamab-cxix — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Infusion-Related Reactions
Advise patients to contact their healthcare provider if they experience signs and symptoms of infusion-related reactions
.
Myelosuppression
Inform patients about the risk of myelosuppression. Advise patients to immediately contact their healthcare provider for a fever of 100.4°F (38°C) or greater or signs or symptoms of bruising or bleeding. Advise patients of the need for periodic monitoring of blood counts
.
Infections
Inform patients about the risk of infections. Advise patients to immediately contact their healthcare provider for a fever of 100.4°F (38°C) or greater or signs or symptoms of infection
.
Embryo-Fetal Toxicity
Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy
.
Advise females of reproductive potential to use effective contraception during treatment with MONJUVI and for at least 3 months after the last dose
. …
Warnings & precautions
Do not take this medicine if: None.
MONJUVI can cause infusion-related reactions
. In L-MIND, infusion-related reactions occurred in 6% of the 81 patients. Eighty percent of infusion-related reactions occurred during cycle 1 or 2. Signs and symptoms included fever, chills, rash, flushing, dyspnea, and hypertension. These reactions were managed with temporary interruption of the infusion and/or with supportive medication.
Premedicate patients prior to starting MONJUVI infusion
. Monitor patients frequently during infusion. Based on the severity of the infusion-related reaction, interrupt or discontinue MONJUVI
. Institute appropriate medical management.
MONJUVI can cause serious or severe myelosuppression, including neutropenia, thrombocytopenia, and anemia
. In L-MIND, Grade 3 neutropenia occurred in 25% of patients, thrombocytopenia in 12%, and anemia in 7%. Grade 4 neutropenia occurred in 25% and thrombocytopenia in 6%. Neutropenia led to treatment discontinuation in 3.7% of patients.
Monitor CBC prior to administration of each treatment cycle and throughout treatment. Monitor patients with neutropenia for signs of infection. Consider granulocyte colony-stimulating factor administration. Withhold MONJUVI based on the severity of the adverse reaction
.
Refer to the lenalidomide prescribing information for dosage modifications.
Fatal and serious infections, including opportunistic infections, occurred in patients during treatment with MONJUVI and following the last dose
.
In L-MIND, 73% of the 81 patients developed an infection. The most frequent infections were respiratory tract infection (24%), urinary tract infection (17%), bronchitis (16%), nasopharyngitis (10%) and pneumonia (10%). Grade 3 or higher infection occurred in 30% of the 81 patients. The most frequent grade 3 or higher infection was pneumonia (7%). …
Tafasitamab-cxix side effects
The following clinically significant adverse reactions are described elsewhere in the labeling:
Infusion-related reactions
Myelosuppression
Infections
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in other clinical trials of another drug and may not reflect the rates observed in practice.
Relapsed or Refractory Diffuse Large B-Cell Lymphoma
The safety of MONJUVI was evaluated in L-MIND
.
Patients (n=81) received MONJUVI 12 mg/kg intravenously in combination with lenalidomide for a maximum of 12 cycles, followed by MONJUVI as monotherapy until disease progression or unacceptable toxicity as follows:
Cycle 1: Days 1, 4, 8, 15 and 22 of the 28-day cycle;
Cycles 2 and 3: Days 1, 8, 15 and 22 of each 28-day cycle;
Cycles 4 and beyond: Days 1 and 15 of each 28-day cycle.
Among patients who received MONJUVI, 57% were exposed for 6 months or longer, 42% were exposed for greater than one year, and 24% were exposed for greater than two years.
Serious adverse reactions occurred in 52% of patients who received MONJUVI. Serious adverse reactions in ≥6% of patients included infections (26%), including pneumonia (7%), and febrile neutropenia (6%). Fatal adverse reactions occurred in 5% of patients who received MONJUVI, including cerebrovascular accident (1.2%), respiratory failure (1.2%), progressive multifocal leukoencephalopathy (1.2%) and sudden death (1.2%). …
About this medicine
Tafasitamab-cxix is a humanized CD19-directed cytolytic monoclonal antibody that contains an IgG1/2 hybrid Fc-domain with 2 amino acid substitutions to modify the Fc-mediated functions of the antibody. It is produced by recombinant DNA technology in mammalian cells (Chinese hamster ovary). Tafasitamab-cxix has a molecular weight of approximately 150 kDa.
MONJUVI (tafasitamab-cxix) for injection is supplied as a sterile, preservative-free, white to slightly yellowish lyophilized powder in a single-dose vial for intravenous use after reconstitution and further dilution. After reconstitution with 5 mL of Sterile Water for Injection, USP, the resulting concentration is 40 mg/mL with a pH of 6.0. Each single-dose vial contains 200 mg tafasitamab-cxix, citric acid monohydrate (3.7 mg), polysorbate 20 (1 mg), sodium citrate dihydrate (31.6 mg) and trehalose dihydrate (378.3 mg). …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ec13ac6b-bfde-4e84-907a-83bd69584d95. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate